The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Targeted Drug ROS1 Inhibitors for NSCLC Market 2024 by Company, Regions, Type and Application, Forecast to 2028
Synopsis
The Targeted Drug ROS1 Inhibitors for NSCLC market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our (Global Info Research) latest study, due to COVID-19 pandemic, the global Targeted Drug ROS1 Inhibitors for NSCLC market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of USD million by 2028 with a CAGR of % during review period. Squamous Cell Carcinoma of NSCLC accounting for % of the Targeted Drug ROS1 Inhibitors for NSCLC global market in 2021, is projected to value USD million by 2028, growing at a % CAGR in next six years. While Crizotinib segment is altered to a % CAGR between 2022 and 2028.
Global key companies of Targeted Drug ROS1 Inhibitors for NSCLC include Roche, Pfizer, Beacon Pharma Limited, Drug International Limted, and Incepta Pharmaceuticals, etc. In terms of revenue, the global top four players hold a share over % in 2021.
Market segmentation
Targeted Drug ROS1 Inhibitors for NSCLC market is split by Type and by Application. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
Crizotinib
Lorlatinib
Entrectinib
Other
Market segment by Application, can be divided into
Squamous Cell Carcinoma of NSCLC
Adenocarcinoma of NSCLC
Large Cell Carcinoma of NSCLC
Market segment by players, this report covers
Roche
Pfizer
Beacon Pharma Limited
Drug International Limted
Incepta Pharmaceuticals
Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 12 chapters:
Chapter 1, to describe Targeted Drug ROS1 Inhibitors for NSCLC product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top players of Targeted Drug ROS1 Inhibitors for NSCLC, with revenue, gross margin and global market share of Targeted Drug ROS1 Inhibitors for NSCLC from 2019 to 2022.
Chapter 3, the Targeted Drug ROS1 Inhibitors for NSCLC competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with revenue and growth rate by Type, application, from 2017 to 2028.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2017 to 2022.and Targeted Drug ROS1 Inhibitors for NSCLC market forecast, by regions, type and application, with revenue, from 2023 to 2028.
Chapter 11 and 12, to describe Targeted Drug ROS1 Inhibitors for NSCLC research findings and conclusion, appendix and data source.
Geographical Area
Global
The Targeted Drug ROS1 Inhibitors for NSCLC market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our (Global Info Research) latest study, due to COVID-19 pandemic, the global Targeted Drug ROS1 Inhibitors for NSCLC market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of USD million by 2028 with a CAGR of % during review period. Squamous Cell Carcinoma of NSCLC accounting for % of the Targeted Drug ROS1 Inhibitors for NSCLC global market in 2021, is projected to value USD million by 2028, growing at a % CAGR in next six years. While Crizotinib segment is altered to a % CAGR between 2022 and 2028.
Global key companies of Targeted Drug ROS1 Inhibitors for NSCLC include Roche, Pfizer, Beacon Pharma Limited, Drug International Limted, and Incepta Pharmaceuticals, etc. In terms of revenue, the global top four players hold a share over % in 2021.
Market segmentation
Targeted Drug ROS1 Inhibitors for NSCLC market is split by Type and by Application. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
Crizotinib
Lorlatinib
Entrectinib
Other
Market segment by Application, can be divided into
Squamous Cell Carcinoma of NSCLC
Adenocarcinoma of NSCLC
Large Cell Carcinoma of NSCLC
Market segment by players, this report covers
Roche
Pfizer
Beacon Pharma Limited
Drug International Limted
Incepta Pharmaceuticals
Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 12 chapters:
Chapter 1, to describe Targeted Drug ROS1 Inhibitors for NSCLC product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top players of Targeted Drug ROS1 Inhibitors for NSCLC, with revenue, gross margin and global market share of Targeted Drug ROS1 Inhibitors for NSCLC from 2019 to 2022.
Chapter 3, the Targeted Drug ROS1 Inhibitors for NSCLC competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with revenue and growth rate by Type, application, from 2017 to 2028.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2017 to 2022.and Targeted Drug ROS1 Inhibitors for NSCLC market forecast, by regions, type and application, with revenue, from 2023 to 2028.
Chapter 11 and 12, to describe Targeted Drug ROS1 Inhibitors for NSCLC research findings and conclusion, appendix and data source.
Geographical Area
Global
Index1 Market Overview
1.1 Product Overview and Scope of Targeted Drug ROS1 Inhibitors for NSCLC
1.2 Classification of Targeted Drug ROS1 Inhibitors for NSCLC by Type
1.2.1 Overview: Global Targeted Drug ROS1 Inhibitors for NSCLC Market Size by Type: 2017 Versus 2021 Versus 2028
1.2.2 Global Targeted Drug ROS1 Inhibitors for NSCLC Revenue Market Share by Type in 2021
1.2.3 Crizotinib
1.2.4 Lorlatinib
1.2.5 Entrectinib
1.2.6 Other
1.3 Global Targeted Drug ROS1 Inhibitors for NSCLC Market by Application
1.3.1 Overview: Global Targeted Drug ROS1 Inhibitors for NSCLC Market Size by Application: 2017 Versus 2021 Versus 2028
1.3.2 Squamous Cell Carcinoma of NSCLC
1.3.3 Adenocarcinoma of NSCLC
1.3.4 Large Cell Carcinoma of NSCLC
1.4 Global Targeted Drug ROS1 Inhibitors for NSCLC Market Size & Forecast
1.5 Global Targeted Drug ROS1 Inhibitors for NSCLC Market Size and Forecast by Region
1.5.1 Global Targeted Drug ROS1 Inhibitors for NSCLC Market Size by Region: 2017 VS 2021 VS 2028
1.5.2 Global Targeted Drug ROS1 Inhibitors for NSCLC Market Size by Region, (2017-2022)
1.5.3 North America Targeted Drug ROS1 Inhibitors for NSCLC Market Size and Prospect (2017-2028)
1.5.4 Europe Targeted Drug ROS1 Inhibitors for NSCLC Market Size and Prospect (2017-2028)
1.5.5 Asia-Pacific Targeted Drug ROS1 Inhibitors for NSCLC Market Size and Prospect (2017-2028)
1.5.6 South America Targeted Drug ROS1 Inhibitors for NSCLC Market Size and Prospect (2017-2028)
1.5.7 Middle East and Africa Targeted Drug ROS1 Inhibitors for NSCLC Market Size and Prospect (2017-2028)
1.6 Market Drivers, Restraints and Trends
1.6.1 Targeted Drug ROS1 Inhibitors for NSCLC Market Drivers
1.6.2 Targeted Drug ROS1 Inhibitors for NSCLC Market Restraints
1.6.3 Targeted Drug ROS1 Inhibitors for NSCLC Trends Analysis
2 Company Profiles
2.1 Roche
2.1.1 Roche Details
2.1.2 Roche Major Business
2.1.3 Roche Targeted Drug ROS1 Inhibitors for NSCLC Product and Solutions
2.1.4 Roche Targeted Drug ROS1 Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.1.5 Roche Recent Developments and Future Plans
2.2 Pfizer
2.2.1 Pfizer Details
2.2.2 Pfizer Major Business
2.2.3 Pfizer Targeted Drug ROS1 Inhibitors for NSCLC Product and Solutions
2.2.4 Pfizer Targeted Drug ROS1 Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.2.5 Pfizer Recent Developments and Future Plans
2.3 Beacon Pharma Limited
2.3.1 Beacon Pharma Limited Details
2.3.2 Beacon Pharma Limited Major Business
2.3.3 Beacon Pharma Limited Targeted Drug ROS1 Inhibitors for NSCLC Product and Solutions
2.3.4 Beacon Pharma Limited Targeted Drug ROS1 Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.3.5 Beacon Pharma Limited Recent Developments and Future Plans
2.4 Drug International Limted
2.4.1 Drug International Limted Details
2.4.2 Drug International Limted Major Business
2.4.3 Drug International Limted Targeted Drug ROS1 Inhibitors for NSCLC Product and Solutions
2.4.4 Drug International Limted Targeted Drug ROS1 Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.4.5 Drug International Limted Recent Developments and Future Plans
2.5 Incepta Pharmaceuticals
2.5.1 Incepta Pharmaceuticals Details
2.5.2 Incepta Pharmaceuticals Major Business
2.5.3 Incepta Pharmaceuticals Targeted Drug ROS1 Inhibitors for NSCLC Product and Solutions
2.5.4 Incepta Pharmaceuticals Targeted Drug ROS1 Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.5.5 Incepta Pharmaceuticals Recent Developments and Future Plans
3 Market Competition, by Players
3.1 Global Targeted Drug ROS1 Inhibitors for NSCLC Revenue and Share by Players (2019, 2020, 2021, and 2022)
3.2 Market Concentration Rate
3.2.1 Top 3 Targeted Drug ROS1 Inhibitors for NSCLC Players Market Share in 2021
3.2.2 Top 10 Targeted Drug ROS1 Inhibitors for NSCLC Players Market Share in 2021
3.2.3 Market Competition Trend
3.3 Targeted Drug ROS1 Inhibitors for NSCLC Players Head Office, Products and Services Provided
3.4 Targeted Drug ROS1 Inhibitors for NSCLC Mergers & Acquisitions
3.5 Targeted Drug ROS1 Inhibitors for NSCLC New Entrants and Expansion Plans
4 Market Size Segment by Type
4.1 Global Targeted Drug ROS1 Inhibitors for NSCLC Revenue and Market Share by Type (2017-2022)
4.2 Global Targeted Drug ROS1 Inhibitors for NSCLC Market Forecast by Type (2023-2028)
5 Market Size Segment by Application
5.1 Global Targeted Drug ROS1 Inhibitors for NSCLC Revenue Market Share by Application (2017-2022)
5.2 Global Targeted Drug ROS1 Inhibitors for NSCLC Market Forecast by Application (2023-2028)
6 North America by Country, by Type, and by Application
6.1 North America Targeted Drug ROS1 Inhibitors for NSCLC Revenue by Type (2017-2028)
6.2 North America Targeted Drug ROS1 Inhibitors for NSCLC Revenue by Application (2017-2028)
6.3 North America Targeted Drug ROS1 Inhibitors for NSCLC Market Size by Country
6.3.1 North America Targeted Drug ROS1 Inhibitors for NSCLC Revenue by Country (2017-2028)
6.3.2 United States Targeted Drug ROS1 Inhibitors for NSCLC Market Size and Forecast (2017-2028)
6.3.3 Canada Targeted Drug ROS1 Inhibitors for NSCLC Market Size and Forecast (2017-2028)
6.3.4 Mexico Targeted Drug ROS1 Inhibitors for NSCLC Market Size and Forecast (2017-2028)
7 Europe by Country, by Type, and by Application
7.1 Europe Targeted Drug ROS1 Inhibitors for NSCLC Revenue by Type (2017-2028)
7.2 Europe Targeted Drug ROS1 Inhibitors for NSCLC Revenue by Application (2017-2028)
7.3 Europe Targeted Drug ROS1 Inhibitors for NSCLC Market Size by Country
7.3.1 Europe Targeted Drug ROS1 Inhibitors for NSCLC Revenue by Country (2017-2028)
7.3.2 Germany Targeted Drug ROS1 Inhibitors for NSCLC Market Size and Forecast (2017-2028)
7.3.3 France Targeted Drug ROS1 Inhibitors for NSCLC Market Size and Forecast (2017-2028)
7.3.4 United Kingdom Targeted Drug ROS1 Inhibitors for NSCLC Market Size and Forecast (2017-2028)
7.3.5 Russia Targeted Drug ROS1 Inhibitors for NSCLC Market Size and Forecast (2017-2028)
7.3.6 Italy Targeted Drug ROS1 Inhibitors for NSCLC Market Size and Forecast (2017-2028)
8 Asia-Pacific by Region, by Type, and by Application
8.1 Asia-Pacific Targeted Drug ROS1 Inhibitors for NSCLC Revenue by Type (2017-2028)
8.2 Asia-Pacific Targeted Drug ROS1 Inhibitors for NSCLC Revenue by Application (2017-2028)
8.3 Asia-Pacific Targeted Drug ROS1 Inhibitors for NSCLC Market Size by Region
8.3.1 Asia-Pacific Targeted Drug ROS1 Inhibitors for NSCLC Revenue by Region (2017-2028)
8.3.2 China Targeted Drug ROS1 Inhibitors for NSCLC Market Size and Forecast (2017-2028)
8.3.3 Japan Targeted Drug ROS1 Inhibitors for NSCLC Market Size and Forecast (2017-2028)
8.3.4 South Korea Targeted Drug ROS1 Inhibitors for NSCLC Market Size and Forecast (2017-2028)
8.3.5 India Targeted Drug ROS1 Inhibitors for NSCLC Market Size and Forecast (2017-2028)
8.3.6 Southeast Asia Targeted Drug ROS1 Inhibitors for NSCLC Market Size and Forecast (2017-2028)
8.3.7 Australia Targeted Drug ROS1 Inhibitors for NSCLC Market Size and Forecast (2017-2028)
9 South America by Country, by Type, and by Application
9.1 South America Targeted Drug ROS1 Inhibitors for NSCLC Revenue by Type (2017-2028)
9.2 South America Targeted Drug ROS1 Inhibitors for NSCLC Revenue by Application (2017-2028)
9.3 South America Targeted Drug ROS1 Inhibitors for NSCLC Market Size by Country
9.3.1 South America Targeted Drug ROS1 Inhibitors for NSCLC Revenue by Country (2017-2028)
9.3.2 Brazil Targeted Drug ROS1 Inhibitors for NSCLC Market Size and Forecast (2017-2028)
9.3.3 Argentina Targeted Drug ROS1 Inhibitors for NSCLC Market Size and Forecast (2017-2028)
10 Middle East & Africa by Country, by Type, and by Application
10.1 Middle East & Africa Targeted Drug ROS1 Inhibitors for NSCLC Revenue by Type (2017-2028)
10.2 Middle East & Africa Targeted Drug ROS1 Inhibitors for NSCLC Revenue by Application (2017-2028)
10.3 Middle East & Africa Targeted Drug ROS1 Inhibitors for NSCLC Market Size by Country
10.3.1 Middle East & Africa Targeted Drug ROS1 Inhibitors for NSCLC Revenue by Country (2017-2028)
10.3.2 Turkey Targeted Drug ROS1 Inhibitors for NSCLC Market Size and Forecast (2017-2028)
10.3.3 Saudi Arabia Targeted Drug ROS1 Inhibitors for NSCLC Market Size and Forecast (2017-2028)
10.3.4 UAE Targeted Drug ROS1 Inhibitors for NSCLC Market Size and Forecast (2017-2028)
11 Research Findings and Conclusion
12 Appendix
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
List of TablesList of Tables
Table 1. Global Targeted Drug ROS1 Inhibitors for NSCLC Revenue by Type, (USD Million), 2017 VS 2021 VS 2028
Table 2. Global Targeted Drug ROS1 Inhibitors for NSCLC Revenue by Application, (USD Million), 2017 VS 2021 VS 2028
Table 3. Global Market Targeted Drug ROS1 Inhibitors for NSCLC Revenue (Million USD) Comparison by Region (2017 VS 2021 VS 2028)
Table 4. Global Targeted Drug ROS1 Inhibitors for NSCLC Revenue (USD Million) by Region (2017-2022)
Table 5. Global Targeted Drug ROS1 Inhibitors for NSCLC Revenue Market Share by Region (2023-2028)
Table 6. Roche Corporate Information, Head Office, and Major Competitors
Table 7. Roche Major Business
Table 8. Roche Targeted Drug ROS1 Inhibitors for NSCLC Product and Solutions
Table 9. Roche Targeted Drug ROS1 Inhibitors for NSCLC Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 10. Pfizer Corporate Information, Head Office, and Major Competitors
Table 11. Pfizer Major Business
Table 12. Pfizer Targeted Drug ROS1 Inhibitors for NSCLC Product and Solutions
Table 13. Pfizer Targeted Drug ROS1 Inhibitors for NSCLC Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 14. Beacon Pharma Limited Corporate Information, Head Office, and Major Competitors
Table 15. Beacon Pharma Limited Major Business
Table 16. Beacon Pharma Limited Targeted Drug ROS1 Inhibitors for NSCLC Product and Solutions
Table 17. Beacon Pharma Limited Targeted Drug ROS1 Inhibitors for NSCLC Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 18. Drug International Limted Corporate Information, Head Office, and Major Competitors
Table 19. Drug International Limted Major Business
Table 20. Drug International Limted Targeted Drug ROS1 Inhibitors for NSCLC Product and Solutions
Table 21. Drug International Limted Targeted Drug ROS1 Inhibitors for NSCLC Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 22. Incepta Pharmaceuticals Corporate Information, Head Office, and Major Competitors
Table 23. Incepta Pharmaceuticals Major Business
Table 24. Incepta Pharmaceuticals Targeted Drug ROS1 Inhibitors for NSCLC Product and Solutions
Table 25. Incepta Pharmaceuticals Targeted Drug ROS1 Inhibitors for NSCLC Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 26. Global Targeted Drug ROS1 Inhibitors for NSCLC Revenue (USD Million) by Players (2019, 2020, 2021, and 2022)
Table 27. Global Targeted Drug ROS1 Inhibitors for NSCLC Revenue Share by Players (2019, 2020, 2021, and 2022)
Table 28. Breakdown of Targeted Drug ROS1 Inhibitors for NSCLC by Company Type (Tier 1, Tier 2 and Tier 3)
Table 29. Targeted Drug ROS1 Inhibitors for NSCLC Players Head Office, Products and Services Provided
Table 30. Targeted Drug ROS1 Inhibitors for NSCLC Mergers & Acquisitions in the Past Five Years
Table 31. Targeted Drug ROS1 Inhibitors for NSCLC New Entrants and Expansion Plans
Table 32. Global Targeted Drug ROS1 Inhibitors for NSCLC Revenue (USD Million) by Type (2017-2022)
Table 33. Global Targeted Drug ROS1 Inhibitors for NSCLC Revenue Share by Type (2017-2022)
Table 34. Global Targeted Drug ROS1 Inhibitors for NSCLC Revenue Forecast by Type (2023-2028)
Table 35. Global Targeted Drug ROS1 Inhibitors for NSCLC Revenue by Application (2017-2022)
Table 36. Global Targeted Drug ROS1 Inhibitors for NSCLC Revenue Forecast by Application (2023-2028)
Table 37. North America Targeted Drug ROS1 Inhibitors for NSCLC Revenue by Type (2017-2022) & (USD Million)
Table 38. North America Targeted Drug ROS1 Inhibitors for NSCLC Revenue by Type (2023-2028) & (USD Million)
Table 39. North America Targeted Drug ROS1 Inhibitors for NSCLC Revenue by Application (2017-2022) & (USD Million)
Table 40. North America Targeted Drug ROS1 Inhibitors for NSCLC Revenue by Application (2023-2028) & (USD Million)
Table 41. North America Targeted Drug ROS1 Inhibitors for NSCLC Revenue by Country (2017-2022) & (USD Million)
Table 42. North America Targeted Drug ROS1 Inhibitors for NSCLC Revenue by Country (2023-2028) & (USD Million)
Table 43. Europe Targeted Drug ROS1 Inhibitors for NSCLC Revenue by Type (2017-2022) & (USD Million)
Table 44. Europe Targeted Drug ROS1 Inhibitors for NSCLC Revenue by Type (2023-2028) & (USD Million)
Table 45. Europe Targeted Drug ROS1 Inhibitors for NSCLC Revenue by Application (2017-2022) & (USD Million)
Table 46. Europe Targeted Drug ROS1 Inhibitors for NSCLC Revenue by Application (2023-2028) & (USD Million)
Table 47. Europe Targeted Drug ROS1 Inhibitors for NSCLC Revenue by Country (2017-2022) & (USD Million)
Table 48. Europe Targeted Drug ROS1 Inhibitors for NSCLC Revenue by Country (2023-2028) & (USD Million)
Table 49. Asia-Pacific Targeted Drug ROS1 Inhibitors for NSCLC Revenue by Type (2017-2022) & (USD Million)
Table 50. Asia-Pacific Targeted Drug ROS1 Inhibitors for NSCLC Revenue by Type (2023-2028) & (USD Million)
Table 51. Asia-Pacific Targeted Drug ROS1 Inhibitors for NSCLC Revenue by Application (2017-2022) & (USD Million)
Table 52. Asia-Pacific Targeted Drug ROS1 Inhibitors for NSCLC Revenue by Application (2023-2028) & (USD Million)
Table 53. Asia-Pacific Targeted Drug ROS1 Inhibitors for NSCLC Revenue by Region (2017-2022) & (USD Million)
Table 54. Asia-Pacific Targeted Drug ROS1 Inhibitors for NSCLC Revenue by Region (2023-2028) & (USD Million)
Table 55. South America Targeted Drug ROS1 Inhibitors for NSCLC Revenue by Type (2017-2022) & (USD Million)
Table 56. South America Targeted Drug ROS1 Inhibitors for NSCLC Revenue by Type (2023-2028) & (USD Million)
Table 57. South America Targeted Drug ROS1 Inhibitors for NSCLC Revenue by Application (2017-2022) & (USD Million)
Table 58. South America Targeted Drug ROS1 Inhibitors for NSCLC Revenue by Application (2023-2028) & (USD Million)
Table 59. South America Targeted Drug ROS1 Inhibitors for NSCLC Revenue by Country (2017-2022) & (USD Million)
Table 60. South America Targeted Drug ROS1 Inhibitors for NSCLC Revenue by Country (2023-2028) & (USD Million)
Table 61. Middle East & Africa Targeted Drug ROS1 Inhibitors for NSCLC Revenue by Type (2017-2022) & (USD Million)
Table 62. Middle East & Africa Targeted Drug ROS1 Inhibitors for NSCLC Revenue by Type (2023-2028) & (USD Million)
Table 63. Middle East & Africa Targeted Drug ROS1 Inhibitors for NSCLC Revenue by Application (2017-2022) & (USD Million)
Table 64. Middle East & Africa Targeted Drug ROS1 Inhibitors for NSCLC Revenue by Application (2023-2028) & (USD Million)
Table 65. Middle East & Africa Targeted Drug ROS1 Inhibitors for NSCLC Revenue by Country (2017-2022) & (USD Million)
Table 66. Middle East & Africa Targeted Drug ROS1 Inhibitors for NSCLC Revenue by Country (2023-2028) & (USD Million)
List of Figures
Figure 1. Targeted Drug ROS1 Inhibitors for NSCLC Picture
Figure 2. Global Targeted Drug ROS1 Inhibitors for NSCLC Revenue Market Share by Type in 2021
Figure 3. Crizotinib
Figure 4. Lorlatinib
Figure 5. Entrectinib
Figure 6. Other
Figure 7. Targeted Drug ROS1 Inhibitors for NSCLC Revenue Market Share by Application in 2021
Figure 8. Squamous Cell Carcinoma of NSCLC Picture
Figure 9. Adenocarcinoma of NSCLC Picture
Figure 10. Large Cell Carcinoma of NSCLC Picture
Figure 11. Global Targeted Drug ROS1 Inhibitors for NSCLC Market Size, (USD Million): 2017 VS 2021 VS 2028
Figure 12. Global Targeted Drug ROS1 Inhibitors for NSCLC Revenue and Forecast (2017-2028) & (USD Million)
Figure 13. Global Targeted Drug ROS1 Inhibitors for NSCLC Revenue Market Share by Region (2017-2028)
Figure 14. Global Targeted Drug ROS1 Inhibitors for NSCLC Revenue Market Share by Region in 2021
Figure 15. North America Targeted Drug ROS1 Inhibitors for NSCLC Revenue (USD Million) and Growth Rate (2017-2028)
Figure 16. Europe Targeted Drug ROS1 Inhibitors for NSCLC Revenue (USD Million) and Growth Rate (2017-2028)
Figure 17. Asia-Pacific Targeted Drug ROS1 Inhibitors for NSCLC Revenue (USD Million) and Growth Rate (2017-2028)
Figure 18. South America Targeted Drug ROS1 Inhibitors for NSCLC Revenue (USD Million) and Growth Rate (2017-2028)
Figure 19. Middle East and Africa Targeted Drug ROS1 Inhibitors for NSCLC Revenue (USD Million) and Growth Rate (2017-2028)
Figure 20. Targeted Drug ROS1 Inhibitors for NSCLC Market Drivers
Figure 21. Targeted Drug ROS1 Inhibitors for NSCLC Market Restraints
Figure 22. Targeted Drug ROS1 Inhibitors for NSCLC Market Trends
Figure 23. Roche Recent Developments and Future Plans
Figure 24. Pfizer Recent Developments and Future Plans
Figure 25. Beacon Pharma Limited Recent Developments and Future Plans
Figure 26. Drug International Limted Recent Developments and Future Plans
Figure 27. Incepta Pharmaceuticals Recent Developments and Future Plans
Figure 28. Global Targeted Drug ROS1 Inhibitors for NSCLC Revenue Share by Players in 2021
Figure 29. Targeted Drug ROS1 Inhibitors for NSCLC Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2021
Figure 30. Global Top 3 Players Targeted Drug ROS1 Inhibitors for NSCLC Revenue Market Share in 2021
Figure 31. Global Top 10 Players Targeted Drug ROS1 Inhibitors for NSCLC Revenue Market Share in 2021
Figure 32. Key Players Market Share Trend (Top 3 Market Share: 2020 VS 2021 VS 2022)
Figure 33. Global Targeted Drug ROS1 Inhibitors for NSCLC Revenue Share by Type in 2021
Figure 34. Global Targeted Drug ROS1 Inhibitors for NSCLC Market Share Forecast by Type (2023-2028)
Figure 35. Global Targeted Drug ROS1 Inhibitors for NSCLC Revenue Share by Application in 2021
Figure 36. Global Targeted Drug ROS1 Inhibitors for NSCLC Market Share Forecast by Application (2023-2028)
Figure 37. North America Targeted Drug ROS1 Inhibitors for NSCLC Sales Market Share by Type (2017-2028)
Figure 38. North America Targeted Drug ROS1 Inhibitors for NSCLC Sales Market Share by Application (2017-2028)
Figure 39. North America Targeted Drug ROS1 Inhibitors for NSCLC Revenue Market Share by Country (2017-2028)
Figure 40. United States Targeted Drug ROS1 Inhibitors for NSCLC Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 41. Canada Targeted Drug ROS1 Inhibitors for NSCLC Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 42. Mexico Targeted Drug ROS1 Inhibitors for NSCLC Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 43. Europe Targeted Drug ROS1 Inhibitors for NSCLC Sales Market Share by Type (2017-2028)
Figure 44. Europe Targeted Drug ROS1 Inhibitors for NSCLC Sales Market Share by Application (2017-2028)
Figure 45. Europe Targeted Drug ROS1 Inhibitors for NSCLC Revenue Market Share by Country (2017-2028)
Figure 46. Germany Targeted Drug ROS1 Inhibitors for NSCLC Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 47. France Targeted Drug ROS1 Inhibitors for NSCLC Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 48. United Kingdom Targeted Drug ROS1 Inhibitors for NSCLC Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 49. Russia Targeted Drug ROS1 Inhibitors for NSCLC Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 50. Italy Targeted Drug ROS1 Inhibitors for NSCLC Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 51. Asia-Pacific Targeted Drug ROS1 Inhibitors for NSCLC Sales Market Share by Type (2017-2028)
Figure 52. Asia-Pacific Targeted Drug ROS1 Inhibitors for NSCLC Sales Market Share by Application (2017-2028)
Figure 53. Asia-Pacific Targeted Drug ROS1 Inhibitors for NSCLC Revenue Market Share by Region (2017-2028)
Figure 54. China Targeted Drug ROS1 Inhibitors for NSCLC Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 55. Japan Targeted Drug ROS1 Inhibitors for NSCLC Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 56. South Korea Targeted Drug ROS1 Inhibitors for NSCLC Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 57. India Targeted Drug ROS1 Inhibitors for NSCLC Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 58. Southeast Asia Targeted Drug ROS1 Inhibitors for NSCLC Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 59. Australia Targeted Drug ROS1 Inhibitors for NSCLC Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 60. South America Targeted Drug ROS1 Inhibitors for NSCLC Sales Market Share by Type (2017-2028)
Figure 61. South America Targeted Drug ROS1 Inhibitors for NSCLC Sales Market Share by Application (2017-2028)
Figure 62. South America Targeted Drug ROS1 Inhibitors for NSCLC Revenue Market Share by Country (2017-2028)
Figure 63. Brazil Targeted Drug ROS1 Inhibitors for NSCLC Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 64. Argentina Targeted Drug ROS1 Inhibitors for NSCLC Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 65. Middle East and Africa Targeted Drug ROS1 Inhibitors for NSCLC Sales Market Share by Type (2017-2028)
Figure 66. Middle East and Africa Targeted Drug ROS1 Inhibitors for NSCLC Sales Market Share by Application (2017-2028)
Figure 67. Middle East and Africa Targeted Drug ROS1 Inhibitors for NSCLC Revenue Market Share by Country (2017-2028)
Figure 68. Turkey Targeted Drug ROS1 Inhibitors for NSCLC Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 69. Saudi Arabia Targeted Drug ROS1 Inhibitors for NSCLC Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 70. UAE Targeted Drug ROS1 Inhibitors for NSCLC Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 71. Methodology
Figure 72. Research Process and Data Source
Published By : GlobalInfoResearch
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
